Skip to main content

Advertisement

Table 3 Inter-patient heterogeneity of apoptotic and DNA repair responses in relation to clinical covariates

From: Intra-patient and inter-patient comparisons of DNA damage response biomarkers in Nasopharynx Cancer (NPC): analysis of NCC0901 randomised controlled trial of induction chemotherapy in locally advanced NPC

Clinical parameters %FLICA p-value %FLICACD4+ p-value %FLICACD8+ p-value ɣH2AX foci 1 Gy 0.5 h p-value ɣH2AX foci 4 Gy 24 h p-value
Age 0.3   0.008   0.1   1.0   1.0
  ≤ 55 y 41.0 (34.40, 45.35)   29.2 (24.95, 38.40)   39.2 (31.15, 51.40)   11.7 (11.09, 13.18)   6.2 (5.17, 7.09)  
  > 55 y 38.6 (31.23, 44.10)   24.8 (18.80, 33.00)   35.8 (26.70, 47.30)   11.8 (11.08, 12.70)   6.2 (5.45, 7.08)  
Gender 0.7   0.6   0.3   0.9   0.5
 Male 40.5 (31.88, 45.93)   27.9 (21.38, 34.95)   37.9 (30.93, 49.30)   11.7 (11.13, 12.79)   6.2 (5.46, 7.08)  
 Female 36.1 (33.70, 42.45)   28.0 (18.90, 34.70)   33.9 (26.80, 44.80)   11.8 (11.02, 13.03)   6.1 (4.58, 7.08)  
T-Category 0.1   0.2   1.0   0.3   0.8
 T0–2 41.6 (33.70, 46.90)   29.0 (21.30, 37.10)   38.4 (30.00, 49.70)   11.8 (10.65, 12.39)   6.1 (5.28, 7.19)  
 T3–4 35.9 (31.07, 42.45)   26.8 (20.30, 33.05)   36.5 (30.50, 48.65)   11.7 (11.17, 13.26)   6.2 (5.21, 7.06)  
N-Category 0.8   0.6   0.7   0.2   0.6
 N0–1 38.9 (31.07, 49.45)   25.6 (19.75, 33.00)   38.4 (26.70, 47.30)   11.4 (10.87, 11.80)   5.7 (5.18, 7.33)  
 N2–3 39.9 (33.55, 44.85)   28.0 (21.30, 35.40)   36.8 (30.70, 49.70)   11.8 (11.09, 13.03)   6.2 (5.27, 7.08)  
TNM stage 0.7   0.6   0.6   1.0   0.3
 III 39.9 (33.47, 44.85)   28.0 (21.00, 34.70)   36.8 (30.70, 47.10)   11.8 (11.02, 12.89)   6.1 (5.21, 7.00)  
 IVA/B 39.3 (32.75, 46.63)   28.0 (21.27, 35.30)   36.8 (29.13, 51.00)   11.7 (11.13, 12.95)   6.5 (5.55, 7.47)  
cfEBV DNA copy number status 1.0^   0.3^   0.7^   0.5^   0.2^
 Positive 38.8 (31.88, 45.15)   27.7 (21.32, 35.30)   39.4 (29.90, 49.55)   11.7 (11.10, 12.69)   6.2 (5.51, 7.23)  
 Negative 38.9 (31.07, 46.90)   31.7 (22.20, 39.90)   35.9 (26.70, 47.30)   11.6 (10.87, 13.18)   5.9 (4.89, 6.26)  
 Not tested 40.4 (34.30, 43.25)   25.9 (18.80, 33.15)   36.2 (30.70, 50.45)   11.8 (11.17, 13.03)   6.7 (5.18, 7.09)  
Treatment assigned 0.6   0.3   0.9   0.8   0.7
 Induction GCP + CRT 40.1 (31.67, 44.98)   26.4 (19.20, 33.92)   36.8 (29.90, 50.58)   11.8 (11.09, 12.95)   6.2 (5.36, 6.88)  
 CRT only 38.6 (33.70, 44.95)   29.0 (21.40, 35.40)   36.9 (30.50, 48.65)   11.7 (11.08, 12.70)   6.1 (5.21, 7.46)  
Sub-group analysis (n = 17)
Severe late xerostomiaa 0.2   0.5   0.2   0.08   0.05
 Control (n = 8) 34.8 (30.70, 38.97)   23.9 (20.63, 33.30)   35.6 (20.97, 45.55)   12.0 (10.79, 13.09)   6.2 (5.50, 7.32)  
 Case (n = 9) 40.4 (33.47, 43.25)   26.3 (25.35, 33.15)   36.8 (34.90, 50.20)   11.1 (10.24, 11.35)   7.7 (6.57, 8.02)  
  1. Reported values are median with corresponding interquartile range (25th percentile, 75th percentile)
  2. P-value calculated using Mann-Whitney U test. Highlighted in bold are values with significant p-values (p≤0.05)
  3. ^P-value calculated excluding the category: Not Tested
  4. aSub-group analysis based on a “Best case–control” design (See Additional file 1: Supplementary methods)
  5. Abbreviations: EBV Epstein-barr virus, GCP gemcitabine, carboplatin, paclitaxel, CRT chemo-radiotherapy